Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma

Pembrolizumab has been widely used to treat advanced urothelial carcinoma that has progressed after first-line platinum-based chemotherapy. Because its clinical benefits are limited, biomarkers that can predict a good response to pembrolizumab are required. The prognostic nutritional index (PNI), ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Kageyama, Susumu, Yoshida, Tetsuya, Kobayashi, Kenichi, Wada, Akinori, Nagasawa, Masayuki, Kubota, Shigehisa, Kusaba, Takuto, Jo, Fumiyasu, Nakagawa, Shota, Johnin, Kazuyoshi, Narita, Mitsuhiro, Kawauchi, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811626/
https://www.ncbi.nlm.nih.gov/pubmed/36644144
http://dx.doi.org/10.3892/ol.2022.13635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811626/
https://www.ncbi.nlm.nih.gov/pubmed/36644144
http://dx.doi.org/10.3892/ol.2022.13635

Ejemplares similares